Therefore, a large panel of drugs are being evaluated as potential therapeutic agents against KMT2A/MLL-R+ AML and ALL, including inhibitors of Menin-MLL1 interaction[25-28]. This evidence concerns the gene KMT2A and acute myeloid leukemia.